| Income Statement | 2025-06-30 | 2024-09-30 | ||
|---|---|---|---|---|
| Reimbursement for expenses - related party | 0 | - | ||
| Total other income (expense) | 276.418 | -90.894 | ||
| Net income (loss) before non-controlling interests | 210.449 | -3,371.651 | ||
| Net income (loss) attributable to non-controlling interests | -67.407 | -67.165 | ||
| Net income (loss) attributable to oncotelic therapeutics, inc | 277.856 | -3,304.486 | ||
| Basic net income (loss) per share attributable to common stock | 0 | -0.01 | ||
| Basic weighted average common stock outstanding | 408,292,720 | 407,289,888 | ||
| Diluted net income per share attributable to common stock | 0 | -0.01 | ||
| Diluted weighted average common stock outstanding | 452,809,058 | 407,289,888 | ||
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)